Spire Wealth Management Has $4.02 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Spire Wealth Management trimmed its holdings in shares of Edwards Lifesciences Co. (NYSE:EWFree Report) by 37.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,073 shares of the medical research company’s stock after selling 34,305 shares during the period. Spire Wealth Management’s holdings in Edwards Lifesciences were worth $4,023,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Banque Cantonale Vaudoise grew its holdings in shares of Edwards Lifesciences by 13.0% during the third quarter. Banque Cantonale Vaudoise now owns 34,264 shares of the medical research company’s stock worth $2,375,000 after purchasing an additional 3,939 shares during the last quarter. Milestone Investment Advisors LLC acquired a new position in Edwards Lifesciences during the 3rd quarter worth about $79,000. Banco Santander S.A. lifted its position in Edwards Lifesciences by 11.0% during the 3rd quarter. Banco Santander S.A. now owns 95,333 shares of the medical research company’s stock worth $6,605,000 after buying an additional 9,481 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC bought a new stake in Edwards Lifesciences during the 3rd quarter worth about $60,971,000. Finally, New York Life Investment Management LLC increased its position in Edwards Lifesciences by 0.5% in the 3rd quarter. New York Life Investment Management LLC now owns 96,247 shares of the medical research company’s stock valued at $6,668,000 after acquiring an additional 467 shares in the last quarter. Institutional investors own 79.25% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of EW opened at $86.09 on Monday. The stock has a 50 day simple moving average of $73.83 and a 200 day simple moving average of $73.54. Edwards Lifesciences Co. has a 52-week low of $60.57 and a 52-week high of $94.87. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.45 and a current ratio of 3.28. The firm has a market capitalization of $52.21 billion, a PE ratio of 36.79, a P/E/G ratio of 4.74 and a beta of 1.04.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 6,000 shares of the stock in a transaction on Monday, November 13th. The shares were sold at an average price of $65.30, for a total transaction of $391,800.00. Following the completion of the sale, the vice president now owns 39,503 shares of the company’s stock, valued at $2,579,545.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, VP Donald E. Bobo, Jr. sold 6,000 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $65.30, for a total value of $391,800.00. Following the sale, the vice president now directly owns 39,503 shares in the company, valued at $2,579,545.90. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Daveen Chopra sold 3,500 shares of the stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $70.00, for a total value of $245,000.00. Following the transaction, the vice president now owns 23,950 shares of the company’s stock, valued at $1,676,500. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 132,283 shares of company stock valued at $9,714,586. 1.29% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. StockNews.com upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Monday, January 22nd. SVB Leerink initiated coverage on Edwards Lifesciences in a research note on Monday, October 16th. They set a “market perform” rating and a $75.00 price target on the stock. Leerink Partnrs reiterated a “market perform” rating on shares of Edwards Lifesciences in a report on Monday, October 16th. Wolfe Research cut Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $57.00 price objective for the company. in a report on Tuesday, November 28th. Finally, Evercore ISI lowered shares of Edwards Lifesciences from an “outperform” rating to an “in-line” rating and reduced their target price for the company from $80.00 to $77.00 in a research note on Thursday, January 4th. One analyst has rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $84.19.

Check Out Our Latest Report on EW

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Further Reading

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWFree Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.